Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients

British Journal of Clinical Pharmacology

Volumn 48, Issue 5, 1999, Pages 712-715

  Villani, P ^a   Regazzi, M B ^a,b   Castelli, F ^c   Viale, P ^c   Torti, C ^c   Seminari, E ^b   Maserati, R ^b  

^a Department of Pharmacology ^*  (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Efavirenz; HIV 1 infection; Nelfinavir; Pharmacokinetic interaction

Indexed keywords

DIDANOSINE; EFAVIRENZ; HYDROXYUREA; NELFINAVIR; STAVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; STEADY STATE; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; NELFINAVIR; OXAZINES; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0032751029     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00071.x     Document Type: Article

References (14)

1. 1 Young SD, Britcher SF, Tran LO, et al. L-743,726 (DMP-266): a novel, highly potent non-nucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39 (12): 2602-2605.
2. 2 Riddler S, Kahn J, Hicks C, et al. Durable clinical anti-HIV-1 activity (72 weeks) and tolerability for Efavirenz (DMP 266) in combination with Indinavir (IDV) [DMP 266-003, Cohort IV]. 12th World AIDS Conference. Geneva, June 28-July 3 1998 (abstract 12359).
3. 3 Haas D, Hicks C, Seekins D, et al. A phase II, double-blind, placebo-controlled, dose-ranging study to assess the antiretroviral activity and safety of Efavirenz (DMP-266) in combination with open-label zidovudine (ZDV) with Lamivudine (3TC) at 24 weeks (DMP 266-005). 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 ((Abstract) 698).
4. 4 Kagan S, Jemsek J, Martin DG, et al. Initial effectiveness and tolerability of nelfinavir (NFV) in combination with efavirenz (EFV,Sustiva,DMP 266) in antiretroviral therapy naive or nucleoside analogue experienced HIV-1 infected patients: characterisation in a phase II, open-label, multi-center study at > 36 weeks (study DMP 266-024). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego September 24-27 1998 ((Abstract) 394).
5. 5 Jemsek J, Kagan S, Martin G, et al. Combination with DMP 266 in antiretroviral therapy naive or nucleoside analogue experienced HIV-infected patients (DMP 266-024). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 24-27 1998 ((Abstract) 1-102).
6. 6 Fiske WD, Benedek IH, White SJ, et al. Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers. 5th Conference on Retroviruses and Opportunistic Infections Chicago, February 1998 (abstract 349).
7. 7 Villani P, Pregnolato M, Banfo S, et al. High-performance liquid chromatography method for analyzing the antiretroviral agent Efavirenz (EFV, DMP 266) in human plasma. Ther Drug Monit 1999; 21: 346-350.
8. 8 Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors ritonavir, saquinavir, and indinavir. Br J Clin Pharmacol 1997; 44: 190-194.
9. 9 Kravcik S, Sahai J, Kerr B, et al. Nelfinavir mesylate (NFV) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HIV+ patients. Fourth Conference on Retroviruses and Opportunistic Infections Washington, DC, January 1997 (abstract 389).
10. 10 Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 1997; 11: F117-F120.
11. 11 Fiske WD, Benedek IH, Joseph JL, et al. Pharmacokinetics of Efavirenz (EFV) and Ritonavir (RTV) after multiple oral doses in healthy volunteers. 12th World AIDS Conference. Geneva, June 28-July 3 1998 (abstract 42269).
12. ™ (efavirenz capsules). Prescribing information 1998 Sep 17.
13. 13 Bacheler LT, Anton E, Baker D, et al. Impact of mutation, Plasma protein binding and pharmacokinetics on clinical efficacy of the HIV-1 non nucleoside reverse trancriptase inhibitor, DMP 266. 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, September 1997 ((Abstract) I-115).
14. 14 Maserati R, Villani P, Seminari E, et al. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS 1999; 13: 12-13.